Scottish Medicines Consortium

Scotland first in the UK to recommend a new treatment option for lung cancer, which could help lower the risk of cancer returning

7 October 2024 -- Scotland, UK -- the Scottish Medicines Consortium has recommended MSD's KEYTRUDA® (pembrolizumab) as monotherapy for the adjuvant treatment of adults with non-small cell lung carcinoma (NSCLC) who are at high risk of recurrence following complete resection and platinum-based chemotherapy. The Scottish Medicines Consortium restricts use to adults whose tumours express programmed...
Delta House 50 West Nile Street Glasgow G1 2NP